The Association for Clinical Oncology (ASCO) is calling on Congress to continue their bipartisan support of federally funded research. Robust, sustained, and predictable funding growth for the National Institutes of Health (NIH) and the National Cancer Institute (NCI) baseline budgets are critical in advancing our nation’s work towards combating, and ultimately curing, diseases like cancer.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
The Association for Clinical Oncology (ASCO) congratulates Robert M. Califf, MD, on his confirmation by the United States Senate to serve as the next Commissioner of the U.S. Food and Drug Administration (FDA).
The Association for Clinical Oncology sent comments to leadership of the United States Senate Committee on Health, Education, Labor, and Pensions (HELP) regarding the Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act (PREVENT Pandemics Act), which aims improve the nation’s public health and medical preparedness systems, in addition to improving the U.S. healthcare system more broadly.
The Association for Clinical Oncology (ASCO) applauds President Biden for his decision to relaunch the Cancer Moonshot with ambitious and worthy goals of reducing the death rate from cancer and improving the experience of patients and families living with cancer.
The Association for Clinical Oncology (ASCO) submitted comments in response to the Centers for Medicare & Medicaid Services’ (CMS) Patient Protection and Affordable Care Act 2023 Notice of Benefit and Payment Parameters proposed rule.
The Centers for Medicare & Medicaid Services (CMS) released the 2023 Medicare Advantage and Part D proposed rule. The proposal aims to advance the administration’s efforts to improve consumer protections, reduce disparities, and improve health equity in Medicare Advantage (MA) and Part D.